Some time ago we blogged about the research into leukemia stem cells done by a team at the Institute for Research in Immunology and Cancer (IRIC) of Université de Montréal. This week, IRIC announced it is moving forward.
In collaboration with the Centre for Commercialization of Regenerative Medicine (CCRM), IRIC Commercialization of Research (IRICoR), has launched ExCellThera, a spin-off company that will improve the process of cord blood stem cell transplantation for patients with acute myeloid leukemia (AML). Click here to discover how stem cells are being used to treat leukemia and other blood disorders on our Toward Treatments page.
“We are excited to be working with CCRM to launch this new IRICoR spin-off company located in Montréal, which includes novel stem cell-expanding molecules that were initially identified and funded at IRIC via an early-stage investment from IRICoR,” Michel Bouvier, CEO of IRICoR, said in the IRIC press release.
ExCellThera is based on novel proprietary intellectual property related to the expansion of stem cells developed by two members of our Foundation’s Science Leadership Council: Dr. Guy Sauvageau, Scientific Director & CEO of IRIC, and Dr. Peter Zandstra, Professor at Institute of Biomaterials and Biomedical Engineering, University of Toronto and Chief Scientific Officer of CCRM.
A Phase I and II clinical trial, designed to test the ability of ExCellThera’s stem cell expansion approach, will begin this year at the Maisonneuve-Rosement Hospital in Montreal, and will grow to include Sainte-Justine Hospital and other centres in the near future. The trial will involve up to 25 patients suffering from AML.